Announcement • Jul 03
Abl Diagnostics Société Anonyme Approves Dividend Distribution for Fiscal Year 2025, Payable on July 7, 2026 ABL Diagnostics At the Annual General Meeting of held on June 30, 2026, shareholders approved all resolutions submitted for their vote, including the payment of a dividend of €0.11 per share for the 2025 fiscal year (compared with €0.05 per share for the 2024 fiscal year), reflecting the Company's improved results and strong financial position. The dividend will be ex-dividend on July 3, 2026, and will be paid on July 7, 2026. Upcoming Dividend • Jun 26
Upcoming dividend of €0.11 per share Eligible shareholders must have bought the stock before 03 July 2026. Payment date: 07 July 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.5%. Lower than top quartile of French dividend payers (5.4%). Higher than average of industry peers (3.1%). Announcement • Jun 02
ABL Diagnostics Société anonyme Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026 ABL Diagnostics Société anonyme provided revenue guidance for the fiscal year ending December 31, 2026. For the year, the company targets total revenue to be €12.27 million, representing a targeted overall growth of +76.5%. Valuation Update With 7 Day Price Move • May 27
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €3.06, the stock trades at a trailing P/E ratio of 50x. Average trailing P/E is 18x in the Trade Distributors industry in France. Total loss to shareholders of 47% over the past three years. Declared Dividend • May 20
Dividend increased to €0.11 Dividend of €0.11 is 120% higher than last year. Ex-date: 3rd July 2026 Payment date: 7th July 2026 Dividend yield will be 2.9%, which is lower than the industry average of 4.8%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Announcement • May 20
ABL Diagnostics Société anonyme, Annual General Meeting, Jun 30, 2026 ABL Diagnostics Société anonyme, Annual General Meeting, Jun 30, 2026. Announcement • May 19
ABL Diagnostics Société anonyme Proposes Dividend for the Financial Year Ended December 31, 2025, Payable on July 7, 2026 ABL Diagnostics announced that its Board of Directors, at its meeting held on April 30, 2026, has decided to propose to the Combined General Meeting to be held on June 30, 2026 the distribution of a dividend of €0.11 per share for the financial year ended December 31, 2025. This proposal, which remains subject to shareholders’ approval, is in line with the Company’s dividend policy, following the first dividend paid in respect of FY2024 in the amount of €0.05 per share. It reflects ABL Diagnostics’ intention to establish a sustainable shareholder return, consistent with its development and financial position. The proposed dividend amounts to approximately €1.77 million in aggregate and would, if approved, be detached on July 3, 2026, with payment scheduled for July 7, 2026, entirely in cash. New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€45.1m market cap, or US$53.1m). New Risk • Jul 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €85.4m (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Upcoming Dividend • Jun 20
Upcoming dividend of €0.05 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 01 July 2025. Trailing yield: 0.9%. Lower than top quartile of French dividend payers (5.4%). Lower than average of industry peers (4.4%). Announcement • May 20
ABL Diagnostics Société anonyme, Annual General Meeting, Jun 24, 2025 ABL Diagnostics Société anonyme, Annual General Meeting, Jun 24, 2025. Location: 9 rue boissy d anglas, paris France Reported Earnings • May 09
Full year 2024 earnings released Full year 2024 results: Revenue: €6.22m (flat on FY 2023). Net income: €285.2k (up 425% from FY 2023). Profit margin: 4.6% (up from 0.9% in FY 2023). Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Trade Distributors industry in France. New Risk • Feb 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin). Market cap is less than US$100m (€82.2m market cap, or US$86.0m). Announcement • Aug 20
ABL Diagnostics Société anonyme, Annual General Meeting, Sep 20, 2024 ABL Diagnostics Société anonyme, Annual General Meeting, Sep 20, 2024. Location: 9 rue boissy d anglas, paris France New Risk • Aug 06
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.9% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (€43.5m market cap, or US$47.5m). New Risk • Jul 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (€45.1m market cap, or US$48.9m). New Risk • Mar 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €51.2m (US$56.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 9.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€51.2m market cap, or US$56.1m). Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment deteriorates as stock falls 67% After last week's 67% share price decline to €3.18, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 8x in the Trade Distributors industry in France. Total returns to shareholders of 64% over the past three years. New Risk • Dec 23
New major risk - Revenue and earnings growth Earnings have declined by 9.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Minor Risk Large one-off items impacting financial results. Board Change • May 22
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Bertrand Aulong is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Apr 24
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Bertrand Aulong is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Mar 09
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Bertrand Aulong is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Jan 09
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Bertrand Aulong is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Sep 02
Advanced Biological Laboratories (ABL) S.A. completed the acquisition of a 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons. Advanced Biological Laboratories (ABL) S.A. agreed to acquire 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons for €3.9 million on October 15, 2021. As of June 14, 2022, Advanced Biological Laboratories (ABL) S.A signed a definitive agreement to acquire 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons. Advanced Biological Laboratories acquired 0.24 million shares of ABL Diagnostics at €15.9 per share. STE Parisienne De Construction Et De Location sold 91.47% stake and seven natural persons sold 5.22% stake. The transaction is subject to shareholder approval of ABL Diagnostics Société anonyme. As of June 13, 2022, Board of Directors of ABL Diagnostics have approved the transaction. As of August 31, 2022, the transaction has been approved by the shareholders of ABL Diagnostics and fulfilled all conditions. Atout Capital advised the shareholders of ABL Diagnostics on the sale of their control block to Advanced Biological Laboratories.
Advanced Biological Laboratories (ABL) S.A. completed the acquisition of a 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons on August 31, 2022. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improved over the past week After last week's 26% share price gain to €5.68, the stock trades at a trailing P/E ratio of 44.2x. Average trailing P/E is 8x in the Trade Distributors industry in France. Total returns to shareholders of 164% over the past year. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorated over the past week After last week's 89% share price decline to €2.90, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 9x in the Trade Distributors industry in France. Total returns to shareholders of 28% over the past year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment deteriorated over the past week After last week's 19% share price decline to €20.20, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 10x in the Trade Distributors industry in France. Total returns to shareholders of 31% over the past three years. Board Change • Mar 28
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Feb 22
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jan 18
Investor sentiment improved over the past week After last week's 32% share price gain to €21.00, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 12x in the Trade Distributors industry in France. Total returns to shareholders of 13% over the past year. Board Change • Dec 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Dec 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €17.80, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 11x in the Trade Distributors industry in France. Total returns to shareholders of 14% over the past three years. Board Change • Nov 02
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Sep 10
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 
